Literature DB >> 19465139

Clinical grade mesenchymal stem cells transdifferentiated under xenofree conditions alleviates motor deficiencies in a rat model of Parkinson's disease.

Prathibha Shetty1, Geeta Ravindran, Shabari Sarang, Anirbhan M Thakur, Harinarayana S Rao, Chandra Viswanathan.   

Abstract

UNLABELLED: Bone marrow derived mesenchymal stem cells (BMMSCs) is a valid, definitive candidate for repair of damaged tissues in degenerative disorders in general and neurological diseases in particular. We have standardized the processing conditions for proliferation of BMMSCs using xenofree medium and checked their in vitro and in vivo neurogenic potential.
METHOD: The proliferative potential of BMMSCs was analyzed using xenofree media and functionality checked by transplantation into Parkinson's disease (PD) animal models. In vitro neuronal differentiation was investigated by neuronal induction media supplemented with growth factors. Differentiated cells were characterized at cellular and molecular levels. In vitro functionality estimated by dopamine secretion.
RESULTS: A pure population of BMMSCs showing an 8-10 fold expansion was obtained using xenofree media. On differentiation to neuronal lineage, they exhibited neuronal morphology. Detectable levels of dopamine (1.93 ng/ml) were secreted into the culture media of differentiated cells. There was a significant behavioural improvement in PD models 3 months post transplantation.
CONCLUSION: Our study demonstrates that BMMSCs can be transdifferentiated efficiently into functional dopaminergic neurons both in vitro and in vivo. This holds immense clinical potential as a replacement therapy for PD and other neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465139     DOI: 10.1016/j.cellbi.2009.05.002

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  16 in total

1.  Umbilical cord matrix derived mesenchymal stem cells can change the cord blood transplant scenario.

Authors:  Shabari Tipnis; Chandra Viswanathan
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

2.  Derivation, expansion and characterization of clinical grade mesenchymal stem cells from umbilical cord matrix using cord blood serum.

Authors:  Khushnuma Cooper; Anish SenMajumdar; Chandra Viswanathan
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

3.  Human umbilical vein-derived dopaminergic-like cell transplantation with nerve growth factor ameliorates motor dysfunction in a rat model of Parkinson's disease.

Authors:  Ming Li; Shi-Zhong Zhang; Yan-Wu Guo; Ying-qian Cai; Zhong-jie Yan; Zhihao Zou; Xiao-Dan Jiang; Yi-Quan Ke; Xu-ying He; Zeng-liang Jin; Guo-hui Lu; Dao-qing Su
Journal:  Neurochem Res       Date:  2010-07-24       Impact factor: 3.996

Review 4.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

5.  Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells.

Authors:  Hanaa H Ahmed; Ahmed M Salem; Hazem M Atta; Emad F Eskandar; Abdel Razik H Farrag; Mohamed A Ghazy; Neveen A Salem; Hadeer A Aglan
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

6.  Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents.

Authors:  Melissa L M Khoo; Helen Tao; Adrian C B Meedeniya; Alan Mackay-Sim; David D F Ma
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

7.  Prospect of cell therapy for Parkinson's disease.

Authors:  Jeanne Adiwinata Pawitan
Journal:  Anat Cell Biol       Date:  2011-12-30

8.  Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy.

Authors:  Masaaki Kitada; Mari Dezawa
Journal:  Parkinsons Dis       Date:  2012-02-28

9.  The Secretome of Bone Marrow and Wharton Jelly Derived Mesenchymal Stem Cells Induces Differentiation and Neurite Outgrowth in SH-SY5Y Cells.

Authors:  Ana O Pires; Andreia Neves-Carvalho; Nuno Sousa; António J Salgado
Journal:  Stem Cells Int       Date:  2014-07-15       Impact factor: 5.443

Review 10.  Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders.

Authors:  Hongzhen Chen; Dewei Shang; Yuguan Wen; Chao Liang
Journal:  Front Cell Dev Biol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.